Aoyama R, Kakizaki Y, Ohnishi A, Izumi Y, Fujita M, Nagata K, Asuka N, Kudo M, Chiba C, Tsushima N
Jpn J Antibiot. 1983 Jun;36(6):1191-8.
Basic and clinical studies on cefotetan (CTT) were carried out and the results were as follows: Absorption and excretion Two patients were given 10 mg/kg of CTT by one shot intravenous injection. At 30 minutes after injection, mean serum level was 76.5 micrograms/ml and the half-life time was 2.3 hours. Mean 6-hour urinary recovery in same patients was 57.5%. Clinical evaluation Forty-two patients were treated with CTT, in doses of 19.2-102.9 mg/kg divided 2-4 times per day for 3-10 days intravenously. Responses were excellent in 14, good in 23, fair in 1, poor in 4, and the overall efficacy rate was 88.1%. As to adverse reaction, urticaria was observed in 1 patient. Abnormal laboratory data noted were elevation of GOT in 1, GOT and GPT in 2, creatinine in 1, and eosinophilia in 3 patients.
对头孢替坦(CTT)进行了基础和临床研究,结果如下:吸收与排泄 两名患者单次静脉注射10mg/kg的CTT。注射后30分钟,平均血清水平为76.5微克/毫升,半衰期为2.3小时。相同患者6小时的平均尿回收率为57.5%。临床评估 42例患者接受CTT治疗,剂量为19.2 - 102.9mg/kg,每天分2 - 4次静脉注射,持续3 - 10天。14例反应极佳,23例良好,1例一般,4例较差,总有效率为88.1%。关于不良反应,1例患者出现荨麻疹。观察到的实验室数据异常包括1例谷草转氨酶(GOT)升高,2例GOT和谷丙转氨酶(GPT)升高,1例肌酐升高,3例嗜酸性粒细胞增多。